Patients with VTE were significantly younger than those with atrial fibrillation (59 vs. 75, p < 0.001), more likely to be female (64% vs. 44%, p = 0.04), more likely to have prior venous rather than arterial thrombosis (p = 0.001), and more likely to have rivaroxaban selected (31.6% vs. 17.4%, p = 0.02) with no other significant differences seen in MPN diagnosis, use of anticoagulation prior to DOAC, or JAK2 V617F mutation status. The gene discussed is JAK2; the disease is myeloproliferative disorder.